Market Cap 743.23M
Revenue (ttm) 294.28M
Net Income (ttm) 367.02M
EPS (ttm) N/A
PE Ratio 10.01
Forward PE 13.63
Profit Margin 124.72%
Debt to Equity Ratio 0.04
Volume 315,500
Avg Vol 366,594
Day's Range N/A - N/A
Shares Out 18.50M
Stochastic %K 55%
Beta 1.16
Analysts Sell
Price Target $55.60

Company Profile

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (I...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 624 1100
Fax: 650 624 1101
Address:
611 Gateway Boulevard, Suite 900, South San Francisco, United States
EnigmaFlow
EnigmaFlow Aug. 10 at 8:02 AM
$CELH $INOD $OSCR $SENS $RIGL Celsius continues expanding in the energy-drink market, Innodata benefits from AI data demand, Oscar Health benefits from digital-health adoption, Senseonics advances continuous glucose-monitoring technology, and Rigel Pharmaceuticals remains focused on specialty therapeutics. I'm watching consumer demand, AI spending, healthcare enrollment, and clinical milestones.
0 · Reply
MaxKlim
MaxKlim Aug. 8 at 5:35 PM
$RIGL vepp -2027 Even taking a conservative slab of $20,000 per month, the annual cost of therapy per person is about $240,000.To achieve a $100 million annual savings, the entire company Pharma for ~416 patients in the US during 2027. At a target market size of 20,000 people per year, that’s just about 2% of the niche.
1 · Reply
B4I4QQTRU18
B4I4QQTRU18 Aug. 8 at 1:31 AM
$RIGL stock up now if you believe. Early Nov-Earnings with Vep Mid Dec-ASH IRAK data. Early Jan- business update with 4.5 months Vep rev. Full year unaudited.
1 · Reply
B4I4QQTRU18
B4I4QQTRU18 Aug. 7 at 8:06 PM
$RIGL gonna be nice when shareholders start getting some of this pie. Give us fiddy Raul.
2 · Reply
B4I4QQTRU18
B4I4QQTRU18 Aug. 7 at 6:47 PM
$RIGL they don’t appear to be backing off.
2 · Reply
lalan93
lalan93 Aug. 7 at 5:47 PM
$RIGL slowly creeping up
1 · Reply
MaxKlim
MaxKlim Aug. 7 at 1:59 PM
$RIGL very hopeful for Alison. Let packs all beautifully and will sell for 80 $ per share and on retirement all!
0 · Reply
MaxKlim
MaxKlim Aug. 7 at 1:53 PM
$RIGL $RIGL $XBI $LABU $SPY $QQQ $RIGL !!! ATTENTION !!! $RIGL 4 approved drugs. unique pipeline. profitable company. sales this year more than 300 million. capitalization of just 750 million. most undervalued company in the sector.
0 · Reply
B4I4QQTRU18
B4I4QQTRU18 Aug. 7 at 1:31 PM
$RIGL it always seems so close.
0 · Reply
Namhguab
Namhguab Aug. 7 at 1:06 PM
$RIGL take away all this hidden dark pool shit and we are at 80 already. They did not want this spiking obviously
0 · Reply
Latest News on RIGL
Rigel Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 5 days ago

Rigel Pharmaceuticals Earnings Call Transcript: Q2 2026


Rigel Pharmaceuticals Earnings release: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 5 days ago

Rigel Pharmaceuticals Earnings release: Q2 2026


Rigel Pharmaceuticals Quarterly report: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 5 days ago

Rigel Pharmaceuticals Quarterly report: Q2 2026


Rigel Pharmaceuticals Slides: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 5 days ago

Rigel Pharmaceuticals Slides: Q2 2026


Rigel Pharmaceuticals reports Q2 EPS 88c, consensus (8c)

2026-08-04T20:25:43.000Z - 5 days ago

Rigel Pharmaceuticals reports Q2 EPS 88c, consensus (8c)


Rigel Reports Second Quarter 2026 Financial Results

Aug 4, 2026, 4:01 PM EDT - 5 days ago

Rigel Reports Second Quarter 2026 Financial Results


Rigel Pharmaceuticals Slides: Corporate presentation

Aug 4, 2026, 9:00 AM EDT - 5 days ago

Rigel Pharmaceuticals Slides: Corporate presentation


Rigel Appoints Board Member Alison L. Hannah, M.D.

Jul 1, 2026, 8:05 AM EDT - 5 weeks ago

Rigel Appoints Board Member Alison L. Hannah, M.D.


Rigel closes license agreement for Veppanu

2026-06-16T20:13:09.000Z - 7 weeks ago

Rigel closes license agreement for Veppanu

ARVN PFE


Rigel Pharmaceuticals Slides: Corporate presentation

Jun 16, 2026, 7:00 AM EDT - 7 weeks ago

Rigel Pharmaceuticals Slides: Corporate presentation


Rigel to Present at the Jefferies Global Healthcare Conference

May 27, 2026, 8:05 AM EDT - 2 months ago

Rigel to Present at the Jefferies Global Healthcare Conference


Rigel Pharmaceuticals Transcript: Investor update

May 12, 2026, 8:00 AM EDT - 3 months ago

Rigel Pharmaceuticals Transcript: Investor update


Rigel Pharmaceuticals Press release: Investor update

May 12, 2026, 8:00 AM EDT - 3 months ago

Rigel Pharmaceuticals Press release: Investor update


Rigel Pharmaceuticals Slides: Corporate presentation

May 12, 2026, 2:00 AM EDT - 3 months ago

Rigel Pharmaceuticals Slides: Corporate presentation


Rigel Pharmaceuticals Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Rigel Pharmaceuticals Earnings Call Transcript: Q1 2026


Rigel Pharmaceuticals Quarterly report: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Rigel Pharmaceuticals Quarterly report: Q1 2026


Rigel Pharmaceuticals Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Rigel Pharmaceuticals Earnings release: Q1 2026


Rigel Pharmaceuticals Slides: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Rigel Pharmaceuticals Slides: Q1 2026


Rigel Pharmaceuticals reports Q1 EPS 44c, consensus 87c

2026-05-05T20:07:48.000Z - 3 months ago

Rigel Pharmaceuticals reports Q1 EPS 44c, consensus 87c


Rigel Reports First Quarter 2026 Financial Results

May 5, 2026, 4:01 PM EDT - 3 months ago

Rigel Reports First Quarter 2026 Financial Results


Rigel Pharmaceuticals Slides: Corporate presentation

May 5, 2026, 7:00 AM EDT - 3 months ago

Rigel Pharmaceuticals Slides: Corporate presentation


Rigel Pharmaceuticals Proxy statement: Proxy filing

Apr 3, 2026, 8:00 AM EDT - 4 months ago

Rigel Pharmaceuticals Proxy statement: Proxy filing


Rigel Pharmaceuticals Proxy statement: Proxy filing

Apr 3, 2026, 8:00 AM EDT - 4 months ago

Rigel Pharmaceuticals Proxy statement: Proxy filing


Rigel Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 3, 2026, 4:30 PM EST - 5 months ago

Rigel Pharmaceuticals Earnings Call Transcript: Q4 2025


Rigel Pharmaceuticals Annual report: Q4 2025

Mar 3, 2026, 4:30 PM EST - 5 months ago

Rigel Pharmaceuticals Annual report: Q4 2025


Rigel Pharmaceuticals Earnings release: Q4 2025

Mar 3, 2026, 4:30 PM EST - 5 months ago

Rigel Pharmaceuticals Earnings release: Q4 2025


Rigel Pharmaceuticals Slides: Q4 2025

Mar 3, 2026, 4:30 PM EST - 5 months ago

Rigel Pharmaceuticals Slides: Q4 2025


Rigel Appoints Michael P. Miller to the Board of Directors

Feb 3, 2026, 8:05 AM EST - 6 months ago

Rigel Appoints Michael P. Miller to the Board of Directors


Rigel Provides Business Update and 2026 Outlook

Jan 12, 2026, 8:05 AM EST - 7 months ago

Rigel Provides Business Update and 2026 Outlook


Rigel Pharmaceuticals Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 7 months ago

Rigel Pharmaceuticals Slides: Corporate presentation


Rigel Pharmaceuticals Slides: Corporate Presentation

Dec 7, 2025, 7:00 AM EST - 8 months ago

Rigel Pharmaceuticals Slides: Corporate Presentation


Rigel Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Rigel Pharmaceuticals Earnings Call Transcript: Q3 2025


Rigel Pharmaceuticals Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Rigel Pharmaceuticals Earnings release: Q3 2025


Rigel Pharmaceuticals Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Rigel Pharmaceuticals Quarterly report: Q3 2025


Rigel Pharmaceuticals Slides: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Rigel Pharmaceuticals Slides: Q3 2025


Overlooked Stock: RIGL Nearly Doubles Stock in August

Aug 15, 2025, 5:20 PM EDT - 1 year ago

Overlooked Stock: RIGL Nearly Doubles Stock in August


The Big 3: OPEN, RIGL, JOBY

Aug 15, 2025, 12:00 PM EDT - 1 year ago

The Big 3: OPEN, RIGL, JOBY

JOBY OPEN


Rigel Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Rigel Pharmaceuticals Earnings Call Transcript: Q2 2025


Rigel Pharmaceuticals Quarterly report: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Rigel Pharmaceuticals Quarterly report: Q2 2025


Rigel Pharmaceuticals Earnings release: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Rigel Pharmaceuticals Earnings release: Q2 2025


Rigel Pharmaceuticals Slides: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 1 year ago

Rigel Pharmaceuticals Slides: Q2 2025


Rigel Pharmaceuticals Earnings Call Transcript: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Rigel Pharmaceuticals Earnings Call Transcript: Q1 2025


Rigel Pharmaceuticals Earnings release: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Rigel Pharmaceuticals Earnings release: Q1 2025


Rigel Pharmaceuticals Quarterly report: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Rigel Pharmaceuticals Quarterly report: Q1 2025


Rigel Pharmaceuticals Slides: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

Rigel Pharmaceuticals Slides: Q1 2025


Rigel Pharmaceuticals Slides: Investor Presentation

May 6, 2025, 7:00 AM EDT - 1 year ago

Rigel Pharmaceuticals Slides: Investor Presentation


Rigel Pharmaceuticals Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Rigel Pharmaceuticals Proxy statement: Proxy Filing


Rigel Pharmaceuticals Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Rigel Pharmaceuticals Proxy statement: Proxy Filing


Rigel Appoints Mark W. Frohlich, M.D.

Mar 10, 2025, 8:05 AM EDT - 1 year ago

Rigel Appoints Mark W. Frohlich, M.D.


Rigel Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Rigel Pharmaceuticals Earnings Call Transcript: Q4 2024


Rigel Pharmaceuticals Earnings release: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Rigel Pharmaceuticals Earnings release: Q4 2024


Rigel Pharmaceuticals Annual report: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Rigel Pharmaceuticals Annual report: Q4 2024


Rigel Pharmaceuticals Slides: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Rigel Pharmaceuticals Slides: Q4 2024


Rigel Pharmaceuticals Slides: FY 2025

Jan 16, 2025, 11:15 AM EST - 1 year ago

Rigel Pharmaceuticals Slides: FY 2025


Rigel Provides Business Update and 2025 Outlook

Jan 13, 2025, 8:05 AM EST - 1 year ago

Rigel Provides Business Update and 2025 Outlook


Rigel Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Rigel Pharmaceuticals Earnings Call Transcript: Q3 2024


Rigel Pharmaceuticals Earnings release: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Rigel Pharmaceuticals Earnings release: Q3 2024


Rigel Pharmaceuticals Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Rigel Pharmaceuticals Quarterly report: Q3 2024


Rigel Pharmaceuticals Slides: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Rigel Pharmaceuticals Slides: Q3 2024


EnigmaFlow
EnigmaFlow Aug. 10 at 8:02 AM
$CELH $INOD $OSCR $SENS $RIGL Celsius continues expanding in the energy-drink market, Innodata benefits from AI data demand, Oscar Health benefits from digital-health adoption, Senseonics advances continuous glucose-monitoring technology, and Rigel Pharmaceuticals remains focused on specialty therapeutics. I'm watching consumer demand, AI spending, healthcare enrollment, and clinical milestones.
0 · Reply
MaxKlim
MaxKlim Aug. 8 at 5:35 PM
$RIGL vepp -2027 Even taking a conservative slab of $20,000 per month, the annual cost of therapy per person is about $240,000.To achieve a $100 million annual savings, the entire company Pharma for ~416 patients in the US during 2027. At a target market size of 20,000 people per year, that’s just about 2% of the niche.
1 · Reply
B4I4QQTRU18
B4I4QQTRU18 Aug. 8 at 1:31 AM
$RIGL stock up now if you believe. Early Nov-Earnings with Vep Mid Dec-ASH IRAK data. Early Jan- business update with 4.5 months Vep rev. Full year unaudited.
1 · Reply
B4I4QQTRU18
B4I4QQTRU18 Aug. 7 at 8:06 PM
$RIGL gonna be nice when shareholders start getting some of this pie. Give us fiddy Raul.
2 · Reply
B4I4QQTRU18
B4I4QQTRU18 Aug. 7 at 6:47 PM
$RIGL they don’t appear to be backing off.
2 · Reply
lalan93
lalan93 Aug. 7 at 5:47 PM
$RIGL slowly creeping up
1 · Reply
MaxKlim
MaxKlim Aug. 7 at 1:59 PM
$RIGL very hopeful for Alison. Let packs all beautifully and will sell for 80 $ per share and on retirement all!
0 · Reply
MaxKlim
MaxKlim Aug. 7 at 1:53 PM
$RIGL $RIGL $XBI $LABU $SPY $QQQ $RIGL !!! ATTENTION !!! $RIGL 4 approved drugs. unique pipeline. profitable company. sales this year more than 300 million. capitalization of just 750 million. most undervalued company in the sector.
0 · Reply
B4I4QQTRU18
B4I4QQTRU18 Aug. 7 at 1:31 PM
$RIGL it always seems so close.
0 · Reply
Namhguab
Namhguab Aug. 7 at 1:06 PM
$RIGL take away all this hidden dark pool shit and we are at 80 already. They did not want this spiking obviously
0 · Reply
Gabriel1234
Gabriel1234 Aug. 6 at 8:23 PM
$RIGL https://finance.biggo.com/quote/RIGL/earnings-call/US_RIGL_2026-08-04?utm_m
0 · Reply
Gabriel1234
Gabriel1234 Aug. 6 at 8:20 PM
$RIGL https://www.marketbeat.com/instant-alerts/filing-empowered-funds-llc-takes-position-in-rigel-pharmaceuticals-inc-rigl-2026-08-06/
0 · Reply
DBales26
DBales26 Aug. 6 at 8:03 PM
$RIGL ~200k share dark pool trade EOD. Been happening over the past month or so.
1 · Reply
lalan93
lalan93 Aug. 6 at 7:51 PM
$RIGL 10min to close and only 241k volume, average is 381.6k. No real insight, just interesting…
0 · Reply
DBales26
DBales26 Aug. 6 at 6:53 PM
$RIGL Since we're clearly not fairly valued even after another blowout earnings report, I wonder how close we're getting to a strategic transaction such as M&A or a Joint Venture. All earnings reports this year have had similar moves right after. To me it seems like the short interest is strategic and will be used to get our share price up when the time comes. I guess it all depends on which large pharmas are most interested in R289 and are under a NDA to view the top-line data, which is most likely being discussed with Alison Hannah as we speak. I think we just need to continue to be patient here and watch everything play out. True organic growth will come but only if new shareholders jump in. Rigel will need to attract them with a major transaction and get them onboard, or just sell the entire company, because the story is still not doing it for the street and we're at a similar share price as 10 years ago under Raul's reign.
1 · Reply
MaxKlim
MaxKlim Aug. 6 at 6:45 PM
0 · Reply
Gabriel1234
Gabriel1234 Aug. 6 at 6:37 PM
$RIGL stock rock to the Moon!!!
0 · Reply
Gabriel1234
Gabriel1234 Aug. 6 at 6:36 PM
$RIGL every moment Vepannu news!!!
1 · Reply
MaxKlim
MaxKlim Aug. 6 at 6:34 PM
0 · Reply
GO_DAWGS
GO_DAWGS Aug. 6 at 6:22 PM
$RIGL time for some market jitters … commence bombing! https://globalmarketnews.com/iran-just-declared-it-will-keep-pursuing-nuclear-weapons/?_bhlid=3d2839ab4b18735265d37212e060de3fb628b345
1 · Reply
MaxKlim
MaxKlim Aug. 6 at 5:51 PM
$RIGL opened additional vacancies. total about 30 positions https://rigel.hrmdirect.com/employment/job-openings.php?search=true&dept=-1&city=-1&state=-1
2 · Reply
christopher18
christopher18 Aug. 6 at 5:43 PM
$RIGL Well, that was fun! Now we bleed....
0 · Reply